07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Epratuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of epratuzumab-RAP...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Veltuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of epratuzumab-RAP...